Why the study?
Does the VALIDATE-SWEDEHEART trial invalidate the use of bivalirudin in myocardial infarction?
Does the VALIDATE-SWEDEHEART trial invalidate the use of bivalirudin in myocardial infarction?
Answers are grounded in this paper and cite their sources.
This editorial discusses the implications of the VALIDATE-SWEDEHEART trial on the use of bivalirudin in patients with myocardial infarction undergoing PCI.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: